Antelope Dx
closedFinancials
Estimates*
EUR | 2020 | 2021 | 2022 |
---|---|---|---|
Revenues | <1m | <1m | - |
% growth | - | 834 % | - |
EBITDA | <1m | - | - |
% EBITDA margin | 2471 % | - | - |
Profit | (6.4m) | (9.0m) | <1m |
% profit margin | (21574 %) | (3229 %) | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
€5.1m | Series A | ||
N/A | €2.5m | Grant | |
N/A | €2.2m | Grant | |
€9.0m | Series B | ||
Total Funding | €18.8m |
Related Content
Recent News about Antelope Dx
EditAntelope Dx operates in the healthcare diagnostics market, focusing on providing advanced at-home testing solutions. The company serves individual consumers who require quick and reliable health diagnostics without visiting a healthcare facility. Antelope Dx's core product is a compact, hand palm-sized testing platform that utilizes photonics technology to deliver highly accurate results within 20 minutes. The platform is designed to be user-friendly, requiring minimal effort to operate, and includes an app that offers guidance and insights for accurate diagnostics. The results are automatically interpreted and stored in a secure cloud environment, facilitating easy sharing with doctors, pharmacists, and health authorities. Antelope Dx's business model revolves around selling these diagnostic devices and potentially offering subscription services for cloud storage and data management. The company generates revenue through the sale of its testing kits and associated digital services, targeting a growing market of health-conscious consumers seeking convenient and reliable home diagnostic solutions.
Keywords: photonics, home diagnostics, cloud connectivity, health insights, user-friendly, rapid testing, secure data, healthcare, digital health, at-home testing.